Metabolic effects of oral contraceptives.
Combination oral contraceptives (OCs) are probably not an independent risk factor for cardiovascular disease but through their metabolic actions, may partly amplify the effects of known risk factors for cardiovascular disease. This review of the literature and our own data indicate that use of high-dose, progestogen-dominant OCs induces a potentially atherogenic lipoprotein profile (high low-density lipoprotein-cholesterol:high-density lipoprotein-cholesterol ratio), mostly attributable to the antiestrogenic action of the progestogen content of these OCs. In contrast, lower-dose combination OCs with reduced amounts of progestogens and slight estrogen dominance, either monophasic or multiphasic, produce strikingly fewer adverse effects on lipoproteins. Moreover, use of low-dose, as opposed to high-dose, OCs results in almost unchanged glucose tolerance, marginally increased or unchanged insulin and glucagon responses to glucose, and probably unchanged levels and activity of peripheral insulin receptors. Further in-depth studies of low-dose OC formulations are mandatory to ascertain reduced metabolic risk of these OCs.
Gaspard
U J
UJ
Department of Obstetrics and Gynecology, State University of Liège, Belgium.
D002318:Cardiovascular Diseases / Q000139:chemically induced; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology*; D003920:Diabetes Mellitus / Q000378:metabolism; D045166:Estradiol Congeners / Q000494:pharmacology; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology; D012307:Risk Factors
D003277:Contraceptives, Oral, Combined; D045166:Estradiol Congeners; D007328:Insulin; D008074:Lipoproteins; D011374:Progesterone; D005947:Glucose